{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:49:50Z","timestamp":1790866190955,"version":"4.1.0"},"reference-count":109,"publisher":"Touch Medical Media, Ltd.","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<p>Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition characterized by the irreversible destruction of the \u03b2 cells of the pancreas, which leads to a lifelong dependency on exogenous insulin. Despite the advancements in insulin delivery methods, the suboptimal outcomes of these methods have triggered the search for therapies that may prevent or reverse the disease. Given the autoimmune aetiology of T1DM, therapies counteracting the immune-mediated destruction of the \u03b2-cells are the obvious target. Although several treatment strategies have been attempted to target cellular, humoral and innate immunity, very few have had a clinically meaningful impact. Of all the available immunomodulatory agents, cluster of differentiation (CD) 3 antibodies have exhibited the most promising preclinical and clinical results. Muromonab-CD3, which also happened to be a murine CD3 antibody, was the first monoclonal antibody approved for clinical use and was primarily indicated for graft rejection. The adverse effects associated with muromonab-CD3 led to its withdrawal. Teplizumab, a newer CD3 antibody, has a better side-effect profile because of its humanized nature and non-Fc- receptor- binding domain. In November 2022, teplizumab became the first immunomodulatory agent to be licensed by the US Food and Drug Administration for delaying the onset of T1DM in high-risk adults and children over 8 years old. The mechanism seems to be enhancing regulatory T-cell activity and promoting immune tolerance. This article reviews the mechanism of action and the clinical trials of teplizumab in individuals with T1DM or at risk of developing the disease.<\/p>","DOI":"10.17925\/ee.2023.19.2.7","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T14:04:15Z","timestamp":1697465055000},"page":"7","source":"Crossref","is-referenced-by-count":40,"title":["Teplizumab in Type 1 Diabetes Mellitus: An Updated Review"],"prefix":"10.17925","volume":"19","author":[{"given":"Simran","family":"Thakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Endocrinology, Indraprastha Apollo Hospitals, New Delhi, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Chopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Endocrinology, Manipal Hospital, Bengaluru, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Endocrinology, JSS Medical College, Mysuru, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Endocrinology, Indraprastha Apollo Hospitals, New Delhi, India","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes.\n                      Lancet\n                      . 2018;391:2449\u201362. DOI: 10.1016\/S0140-6736(18)31320-5.","DOI":"10.1016\/S0140-6736(18)31320-5"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: Population based study.\n                      BMJ\n                      . 2018;362:k1497. DOI: 10.1136\/bmj.k1497.","DOI":"10.1136\/bmj.k1497"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Harjutsalo V, Reunanen A, Tuomilehto J. Differential transmission of type 1 diabetes from diabetic fathers and mothers to their offspring.\n                      Diabetes\n                      . 2006;55:1517\u201324. DOI: 10.2337\/db05-1296.","DOI":"10.2337\/db05-1296"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Harjutsalo V, Lammi N, Karvonen M, Groop PH. Age at onset of type 1 diabetes in parents and recurrence risk in offspring.\n                      Diabetes\n                      . 2010;59:210\u20134. DOI: 10.2337\/db09-0344.","DOI":"10.2337\/db09-0344"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Koczwara K, Bonifacio E, Ziegler AG. Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes.\n                      Diabetes\n                      . 2004;53:1\u20134. DOI: 10.2337\/diabetes.53.1.1.","DOI":"10.2337\/diabetes.53.1.1"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Steck AK, Barriga KJ, Emery LM, et al. Secondary attack rate of type 1 diabetes in Colorado families.\n                      Diabetes Care\n                      . 2005;28:296\u2013300. DOI: 10.2337\/diacare.28.2.296.","DOI":"10.2337\/diacare.28.2.296"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Turtinen M, H\u00e4rk\u00f6nen T, Parkkola A, et al. Characteristics of familial type 1 diabetes: Effects of the relationship to the affected family member on phenotype and genotype at diagnosis.\n                      Diabetologia\n                      . 2019;62:2025\u201339. DOI: 10.1007\/s00125-019-4952-8.","DOI":"10.1007\/s00125-019-4952-8"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Redondo MJ, Jeffrey J, Fain PR, et al. Concordance for islet autoimmunity among monozygotic twins.\n                      N Engl J Med\n                      . 2008;359:2849\u201350. DOI: 10.1056\/NEJMc0805398.","DOI":"10.1056\/NEJMc0805398"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Olmos P, A'Hern R, Heaton DA, et al. The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins.\n                      Diabetologia\n                      . 1988;31:747\u201350. DOI: 10.1007\/BF00274777.","DOI":"10.1007\/BF00274777"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Triolo TM, Fouts A, Pyle L, et al. Identical and nonidentical twins: Risk and factors involved in development of islet autoimmunity and type 1 diabetes.\n                      Diabetes Care\n                      . 2019;42:192\u20139. DOI: 10.2337\/dc18-0288.","DOI":"10.2337\/dc18-0288"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Noble JA, Erlich HA. Genetics of type 1 diabetes.\n                      Cold Spring Harb Perspect Med\n                      . 2012;2:a007732. DOI: 10.1101\/cshperspect.a007732.","DOI":"10.1101\/cshperspect.a007732"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lampasona V, Liberati D. Islet autoantibodies.\n                      Curr Diab Rep\n                      . 2016;16:53. DOI: 10.1007\/s11892-016-0738-2.","DOI":"10.1007\/s11892-016-0738-2"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"P\u00f6ll\u00e4nen PM, Ryh\u00e4nen SJ, Toppari J, et al. Dynamics of islet autoantibodies during prospective follow-up from birth to age 15 years.\n                      J Clin Endocrinol Metab\n                      . 2020;105:e4638\u201351. DOI: 10.1210\/clinem\/dgaa624.","DOI":"10.1210\/clinem\/dgaa624"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Vehik K, Bonifacio E, Lernmark \u00c5, et al. Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY study.\n                      Diabetes Care\n                      . 2020;43:2066\u201373. DOI: 10.2337\/dc19-2547.","DOI":"10.2337\/figshare.12302405"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Jia X, Gu Y, High H, Yu L. Islet autoantibodies in disease prediction and pathogenesis.\n                      Diabetol Int\n                      . 2020;11:6\u201310. DOI: 10.1007\/s13340-019-00414-9.","DOI":"10.1007\/s13340-019-00414-9"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Roep BO. The role of T-cells in the pathogenesis of type 1 diabetes: From cause to cure.\n                      Diabetologia\n                      . 2003;46:305\u201321. DOI: 10.1007\/s00125-003-1089-5.","DOI":"10.1007\/s00125-003-1089-5"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Giwa AM, Ahmed R, Omidian Z, et al. Current understandings of the pathogenesis of type 1 diabetes: Genetics to environment.\n                      World J Diabetes\n                      . 2020;11:13\u201325. DOI: 10.4239\/wjd.v11.i1.13.","DOI":"10.4239\/wjd.v11.i1.13"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Pugliese A. Autoreactive T cells in type 1 diabetes.\n                      J Clin Invest\n                      . 2017;127:2881\u201391. DOI: 10.1172\/JCI94549.","DOI":"10.1172\/JCI94549"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Rawshani A, Sattar N, Franz\u00e9n S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: A nationwide, register-based cohort study.\n                      Lancet\n                      . 2018;392:477\u201386. DOI: 10.1016\/S0140-6736(18)31506-X.","DOI":"10.1016\/S0140-6736(18)31506-X"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Cook JJ, Hudson I, Harrison LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes.\n                      Diabetes\n                      . 1989;38:779\u201383. DOI: 10.2337\/diab.38.6.779.","DOI":"10.2337\/diabetes.38.6.779"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.\n                      Diabetes Care\n                      . 2010;33:826\u201332. DOI: 10.2337\/dc09-1349.","DOI":"10.2337\/dc09-1349"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Bougn\u00e8res PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.\n                      Diabetes\n                      . 1990;39:1264\u201372. DOI: 10.2337\/diab.39.10.1264.","DOI":"10.2337\/diab.39.10.1264"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Christie MR, M\u00f8lvig J, Hawkes CJ, et al. IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin.\n                      Diabetes Care\n                      . 2002;25:1192\u20137. DOI: 10.2337\/diacare.25.7.1192.","DOI":"10.2337\/diacare.25.7.1192"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes.\n                      Diabetes Care\n                      . 2009;32:1244\u20139. DOI: 10.2337\/dc09-0054.","DOI":"10.2337\/dc09-0054"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials.\n                      Lancet\n                      . 2013;381:1905\u201315. DOI: 10.1016\/S0140-6736(13)60023-9.","DOI":"10.1016\/S0140-6736(13)60023-9"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.\n                      N Engl J Med\n                      . 2009;361:2143\u201352. DOI: 10.1056\/NEJMoa0904452.","DOI":"10.1056\/NEJMoa0904452"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial.\n                      Lancet\n                      . 2011;378:319\u201327. DOI: 10.1016\/S0140-6736(11)60895-7.","DOI":"10.1016\/S0140-6736(11)60895-7"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial.\n                      Lancet\n                      . 2001;358:1749\u201353. DOI: 10.1016\/S0140-6736(01)06801-5.","DOI":"10.1016\/S0140-6736(01)06801-5"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial.\n                      Lancet\n                      . 2011;378:412\u20139. DOI: 10.1016\/S0140-6736(11)60886-6.","DOI":"10.1016\/S0140-6736(11)60886-6"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Keymeulen B, van Maurik A, Inman D, et al. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.\n                      Diabetologia\n                      . 2021;64:313\u201324. DOI: 10.1007\/s00125-020-05317-y.","DOI":"10.1007\/s00125-020-05317-y"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes.\n                      N Engl J Med\n                      . 2019;381:603\u201313. DOI: 10.1056\/NEJMoa1902226.","DOI":"10.1056\/NEJMoa1902226"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Deligne C, You S, Mallone R. Personalized immunotherapies for type 1 diabetes: Who, what, when, and how?\n                      J Pers Med\n                      . 2022;12:542. DOI: 10.3390\/jpm12040542.","DOI":"10.3390\/jpm12040542"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Hirsch JS. FDA approves teplizumab: A milestone in type 1 diabetes.\n                      Lancet Diabetes Endocrinol\n                      . 2023;11:18. DOI: 10.1016\/S2213-8587(22)00351-5.","DOI":"10.1016\/S2213-8587(22)00351-5"},{"key":"ref34","unstructured":"U.S. Food and Drug Administration. FDA approves first drug that can delay onset of type 1 diabetes. 2022. Available at: www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-can-delay-onset-type-1-diabetes (Date last accessed: 3 August 2023)."},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Cabrera SM, Rigby MR, Mirmira RG. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.\n                      Curr Mol Med\n                      . 2012;12:1261\u201372. DOI: 10.2174\/156652412803833634.","DOI":"10.2174\/156652412803833634"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders.\n                      Diabetes\n                      . 2013;62:3766\u201374. DOI: 10.2337\/db13-0345.","DOI":"10.2337\/db13-0345"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial.\n                      Lancet\n                      . 2011;378:487\u201397. DOI: 10.1016\/S0140-6736(11)60931-8.","DOI":"10.1016\/S0140-6736(11)60931-8"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Kim S-S, Hudgins AD, Yang J, et al. A comprehensive integrated post-GWAS analysis of type 1 diabetes reveals enhancer-based immune dysregulation.\n                      PLoS One\n                      . 2021;16:e0257265. DOI: 10.1371\/journal.pone.0257265.","DOI":"10.1371\/journal.pone.0257265"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Dalili S, Koohmanaee S, Mirmonsef SG, et al. Preventable prenatal and neonatal risk factors of type 1 diabetes in childhood.\n                      Int J Prev Med\n                      . 2023;14:19. DOI: 10.4103\/ijpvm.ijpvm_190_21.","DOI":"10.4103\/ijpvm.ijpvm_190_21"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Gerstein HC, VanderMeulen J. The relationship between cow's milk exposure and type 1 diabetes.\n                      Diabet Med\n                      . 1996;13:23\u20139. DOI: 10.1002\/(SICI)1096-9136(199601)13:1<23::AID-DIA4>3.0.CO;2-D.","DOI":"10.1002\/(SICI)1096-9136(199601)13:1<23::AID-DIA4>3.0.CO;2-D"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Esposito S, Toni G, Tascini G, et al. Environmental factors associated with type 1 diabetes.\n                      Front Endocrinol (Lausanne)\n                      . 2019;10:592. DOI: 10.3389\/fendo.2019.00592.","DOI":"10.3389\/fendo.2019.00592"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Esposito S, Mariotti Zani E, Torelli L, et al. Childhood vaccinations and type 1 diabetes.\n                      Front Immunol\n                      . 2021;12:667889. DOI: 10.3389\/fimmu.2021.667889.","DOI":"10.3389\/fimmu.2021.667889"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"\u00c7i\u00e7ekli \u0130, Durusoy R. Breastfeeding, nutrition and type 1 diabetes: A case-control study in Izmir, Turkey.\n                      Int Breastfeed J\n                      . 2022;17:42. DOI: 10.1186\/s13006-022-00470-z.","DOI":"10.1186\/s13006-022-00470-z"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Quinn LM, Wong FS, Narendran P. Environmental determinants of type 1 diabetes: From association to proving causality.\n                      Front Immunol\n                      . 2021;12:737964. DOI: 10.3389\/fimmu.2021.737964.","DOI":"10.3389\/fimmu.2021.737964"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes.\n                      Lancet\n                      . 2016;387:2340\u20138. DOI: 10.1016\/S0140-6736(16)30507-4.","DOI":"10.1016\/S0140-6736(16)30507-4"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"He LP, Song YX, Zhu T, et al. Progress in the relationship between vitamin D deficiency and the incidence of type 1 diabetes mellitus in children.\n                      J Diabetes Res\n                      . 2022;2022:5953562. DOI: 10.1155\/2022\/5953562.","DOI":"10.1155\/2022\/5953562"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Issazadeh-Navikas S, Teimer R, Bockermann R. Influence of dietary components on regulatory T cells.\n                      Mol Med\n                      . 2012;18:95\u2013110. DOI: 10.2119\/molmed.2011.00311.","DOI":"10.2119\/molmed.2011.00311"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation\/blockade in autoimmune disease therapy.\n                      Immunol Rev\n                      . 2009;229:337\u201355. DOI: 10.1111\/j.1600-065X.2009.00773.x.","DOI":"10.1111\/j.1600-065X.2009.00773.x"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Karaoz E, Ok\u00e7u A, Saglam O, et al. Pancreatic islet derived stem cells can express co-stimulatory molecules of antigen-presenting cells.\n                      Transplant Proc\n                      . 2010;42:3663\u201370. DOI: 10.1016\/j.transproceed.2010.07.093.","DOI":"10.1016\/j.transproceed.2010.07.093"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus.\n                      Nat Rev Endocrinol\n                      . 2019;15:635\u201350. DOI: 10.1038\/s41574-019-0254-y.","DOI":"10.1038\/s41574-019-0254-y"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Peters L, Posgai A, Brusko TM. Islet-immune interactions in type 1 diabetes: The nexus of beta cell destruction.\n                      Clin Exp Immunol\n                      . 2019;198:326\u201340. DOI: 10.1111\/cei.13349.","DOI":"10.1111\/cei.13349"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Pugliese A. Central and peripheral autoantigen presentation in immune tolerance.\n                      Immunology\n                      . 2004;111:138\u201346. DOI: 10.1111\/j.0019-2805.2003.01804.x.","DOI":"10.1111\/j.0019-2805.2003.01804.x"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Chatenoud L. Natural and induced T CD4+CD25+FOXP3+ regulatory T cells.\n                      Methods Mol Biol\n                      . 2011;677:3\u201313. DOI: 10.1007\/978-1-60761-869-0_1.","DOI":"10.1007\/978-1-60761-869-0_1"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Visperas A, Vignali DAA. Are regulatory T cells defective in type 1 diabetes and can we fix them?\n                      J Immunol\n                      . 2016;197:3762\u201370. DOI: 10.4049\/jimmunol.1601118.","DOI":"10.4049\/jimmunol.1601118"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Dwyer CJ, Ward NC, Pugliese A, Malek TR. Promoting immune regulation in type 1 diabetes using low-dose interleukin-2.\n                      Curr Diab Rep\n                      . 2016;16:46. DOI: 10.1007\/s11892-016-0739-1.","DOI":"10.1007\/s11892-016-0739-1"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Ryba-Stanis \u0142awowska M, Rybarczyk-Kapturska K, My \u015bliwiec M, My \u015bliwska J. Elevated levels of serum IL-12 and IL-18 are associated with lower frequencies of CD4(+)CD25(High)FOXP3(+) regulatory T cells in young patients with type 1 diabetes.\n                      Inflammation\n                      . 2014;37:1513\u201320. DOI: 10.1007\/s10753-014-9878-1.","DOI":"10.1007\/s10753-014-9878-1"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Xufr\u00e9 C, Costa M, Roura-Mir C, et al. Low frequency of GITR+ T cells in ex vivo and in vitro expanded Treg cells from type 1 diabetic patients.\n                      Int Immunol\n                      . 2013;25:563\u201374. DOI: 10.1093\/intimm\/dxt020.","DOI":"10.1093\/intimm\/dxt020"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Viisanen T, Gazali AM, Ihantola E-L, et al. FOXP3+ regulatory T cell compartment is altered in children with newly diagnosed type 1 diabetes but not in autoantibody-positive at-risk children.\n                      Front Immunol\n                      . 2019;10:19. DOI: 10.3389\/fimmu.2019.00019.","DOI":"10.3389\/fimmu.2019.00019"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Skyler JS. The compelling case for anti-CD3 in type 1 diabetes.\n                      Diabetes\n                      . 2013;62:3656\u20137. DOI: 10.2337\/db13-1157.","DOI":"10.2337\/db13-1157"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.\n                      J Immunol\n                      . 2011;187:2015\u201322. DOI: 10.4049\/jimmunol.1100713.","DOI":"10.4049\/jimmunol.1100713"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.\n                      Diabetes Care\n                      . 2015;38:1964\u201374. DOI: 10.2337\/dc15-1419.","DOI":"10.2337\/dc15-1419"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease.\n                      N Engl J Med\n                      . 1986;314:1360\u20138. DOI: 10.1056\/NEJM198605223142106.","DOI":"10.1056\/NEJM198605223142106"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Steck AK, Vehik K, Bonifacio E, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The environmental determinants of diabetes in the young (TEDDY).\n                      Diabetes Care\n                      . 2015;38:808\u201313. DOI: 10.2337\/dc14-2426.","DOI":"10.2337\/dc14-2426"},{"key":"ref64","unstructured":"Pozzilli P, Visalli N, Buzzetti R, et al. Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years.\n                      Diabete Metab\n                      . 1995;21:47\u20139."},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Carel JC, Boitard C, Eisenbarth G, et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children.\n                      J Autoimmun\n                      . 1996;9:739\u201345. DOI: 10.1006\/jaut.1996.0096.","DOI":"10.1006\/jaut.1996.0096"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Assfalg R, Knoop J, Hoffman KL, et al. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial.\n                      Diabetologia\n                      . 2021;64:1079\u201392. DOI: 10.1007\/s00125-020-05376-1.","DOI":"10.1007\/s00125-020-05376-1"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Vehik K, Cuthbertson D, Ruhlig H, et al. Long-term outcome of individuals treated with oral insulin: Diabetes prevention trial-type 1 (DPT-1) oral insulin trial.\n                      Diabetes Care\n                      . 2011;34:1585\u201390. DOI: 10.2337\/dc11-0523.","DOI":"10.2337\/dc11-0523"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"N\u00e4nt\u00f6-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial.\n                      Lancet\n                      . 2008;372:1746\u201355. DOI: 10.1016\/S0140-6736(08)61309-4.","DOI":"10.1016\/S0140-6736(08)61309-4"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Koulmanda M, Bhasin M, Awdeh Z, et al. The role of TNF- \u03b1 in mice with type 1- and 2- diabetes.\n                      PLoS One\n                      . 2012;7:e33254. DOI: 10.1371\/journal.pone.0033254.","DOI":"10.1371\/journal.pone.0033254"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Ablamunits V, Henegariu O, Hansen JB, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: Evidence of improved immune regulation.\n                      Diabetes\n                      . 2012;61:145\u201354. DOI: 10.2337\/db11-1033.","DOI":"10.2337\/db11-1033"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"van Asseldonk EJP, van Poppel PCM, Ballak DB, et al. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus.\n                      Clin Immunol\n                      . 2015;160:155\u201362. DOI: 10.1016\/j.clim.2015.06.003.","DOI":"10.1016\/j.clim.2015.06.003"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells.\n                      Novartis Found Symp\n                      . 2003;252:279\u201386.","DOI":"10.1002\/0470871628.ch21"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Grinberg-Bleyer Y, Saadoun D, Baeyens A, et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs.\n                      J Clin Invest\n                      . 2010;120:4558\u201368. DOI: 10.1172\/JCI42945.","DOI":"10.1172\/JCI42945"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Yang SJ, Singh AK, Drow T. Pancreatic islet-specific engineered tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models.\n                      Sci Transl Med\n                      . 2022;14:665. DOI: 10.1126\/scitranslmed.abn1716.","DOI":"10.1126\/scitranslmed.abn1716"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Simon G, Parker M, Ramiya V, et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation.\n                      Diabetes\n                      . 2008;57:405\u201314. DOI: 10.2337\/db06-1384.","DOI":"10.2337\/db06-1384"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Harada M, Makino S. Suppression of overt diabetes in NOD mice by anti-thymocyte serum or anti-Thy 1, 2 antibody.\n                      Jikken Dobutsu\n                      . 1986;35:501\u20134. DOI: 10.1538\/expanim1978.35.4_501.","DOI":"10.1538\/expanim1978.35.4_501"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Liu T, Cong M, Sun G, et al. Combination of double negative T cells and anti-thymocyte serum reverses type 1 diabetes in NOD mice.\n                      J Transl Med\n                      . 2016;14:57. DOI: 10.1186\/s12967-016-0815-y.","DOI":"10.1186\/s12967-016-0815-y"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Couri CEB, Oliveira MCB, Stracieri ABPL, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.\n                      JAMA\n                      . 2009;301:1573\u20139. DOI: 10.1001\/jama.2009.470.","DOI":"10.1001\/jama.2009.470"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.\n                      J Clin Invest\n                      . 2015;125:3285\u201396. DOI: 10.1172\/JCI81722.","DOI":"10.1172\/JCI81722"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.\n                      Transplantation\n                      . 1981;32:535\u20139. DOI: 10.1097\/00007890-198112000-00018.","DOI":"10.1097\/00007890-198112000-00018"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Norman DJ, Shield CF, Barry JM, et al. Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection.\n                      Nephron\n                      . 1987;46(Suppl. 1):41\u20137. DOI: 10.1159\/000184433.","DOI":"10.1159\/000184433"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Caillat-Zucman S, Blumenfeld N, Legendre C, et al. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells.\n                      Transplantation\n                      . 1990;49:156\u201360.","DOI":"10.1097\/00007890-199001000-00035"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.\n                      Transplantation\n                      . 1990;49:697\u2013702. DOI: 10.1097\/00007890-199004000-00009.","DOI":"10.1097\/00007890-199004000-00009"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: From bench to bedside.\n                      Immunotherapy\n                      . 2016;8:889\u2013906. DOI: 10.2217\/imt-2016-0049.","DOI":"10.2217\/imt-2016-0049"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Kaufman A, Herold KC. Anti-CD3 mAbs for treatment of type 1 diabetes.\n                      Diabetes Metab Res Rev\n                      . 2009;25:302\u20136. DOI: 10.1002\/dmrr.933.","DOI":"10.1002\/dmrr.933"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Masharani UB, Becker J. Teplizumab therapy for type 1 diabetes.\n                      Expert Opin Biol Ther\n                      . 2010;10:459\u201365. DOI: 10.1517\/14712591003598843.","DOI":"10.1517\/14712591003598843"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Miller SA, St Onge E. Otelixizumab: A novel agent for the prevention of type 1 diabetes mellitus.\n                      Expert Opin Biol Ther\n                      . 2011;11:1525\u201332. DOI: 10.1517\/14712598.2011.610789.","DOI":"10.1517\/14712598.2011.610789"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Vlasakakis G, Napolitano A, Barnard R, et al. Target engagement and cellular fate of otelixizumab: A repeat dose escalation study of an anti-CD3 \u03b5 mAb in new-onset type 1 diabetes mellitus patients.\n                      Br J Clin Pharmacol\n                      . 2019;85:704\u201314. DOI: 10.1111\/bcp.13842.","DOI":"10.1111\/bcp.13842"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Woodle ES, Bluestone JA, Zivin RA, et al. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): Initial clinical experience.\n                      Transplant Proc\n                      . 1998;30:1369\u201370. DOI: 10.1016\/s0041-1345(98)00278-4.","DOI":"10.1016\/S0041-1345(98)00278-4"},{"key":"ref90","unstructured":"AstraZeneca. Tezepelumab granted Breakthrough Therapy Designation by US FDA. 2018. Available at: www.astrazeneca.com\/media-centre\/press-releases\/2018\/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-07092018.html (Date last accessed: 3 August 2023)."},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Anderson MS, Bluestone JA. The NOD Mouse: A model of immune dysregulation.\n                      Annu Rev Immunol\n                      . 2005;23:447\u201385. DOI: 10.1146\/annurev.immunol.23.021704.115643.","DOI":"10.1146\/annurev.immunol.23.021704.115643"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Hayward AR, Shreiber M. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes.\n                      J Immunol\n                      . 1989;143:1555\u20139. DOI: 10.4049\/jimmunol.143.5.1555.","DOI":"10.4049\/jimmunol.143.5.1555"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice.\n                      J Immunol\n                      . 1997;158:2947\u201354. DOI: 10.4049\/jimmunol.158.6.2947.","DOI":"10.4049\/jimmunol.158.6.2947"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.\n                      N Engl J Med\n                      . 2002;346:1692\u20138. DOI: 10.1056\/NEJMoa012864.","DOI":"10.1056\/NEJMoa012864"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Hagopian W, Ferry RJ, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: Two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial.\n                      Diabetes\n                      . 2013;62:3901\u20138. DOI: 10.2337\/db13-0236.","DOI":"10.2337\/db13-0236"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.\n                      Sci Transl Med\n                      . 2021;13:eabc8980. DOI: 10.1126\/scitranslmed.abc8980.","DOI":"10.1126\/scitranslmed.abc8980"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Nourelden AZ, Elshanbary AA, El-Sherif L, et al. Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: A systematic review and meta-analysis.\n                      Endocr Metab Immune Disord Drug Targets\n                      . 2021;21:1895\u2013904. DOI: 10.2174\/1871530320999201209222921.","DOI":"10.2174\/1871530320999201209222921"},{"key":"ref98","unstructured":"ClinicalTrials.gov. Recent-onset type 1 diabetes trial evaluating efficacy and safety of Teplizumab (PROTECT). ClinicalTrials.gov identifier: NCT03875729. Available at: www.clinicaltrials.gov\/study\/NCT03875729 (Date last accessed: 23 August 2023)."},{"key":"ref99","unstructured":"Newton W. Delaying type 1 diabetes progression: Major trial readouts to watch in 2023. 2023. Available at: www.clinicaltrialsarena.com\/features\/type-1-diabetes-progression-trials-to-watch-2023\/ (Date last accessed: 3 August 2023)."},{"key":"ref100","unstructured":"ClinicalTrials.gov. Teplizumab for prevention of type 1 diabetes in relatives \"at-risk\". ClinicalTrials.gov identifier: NCT01030861. 2020. Available at: https:\/\/clinicaltrials.gov\/study\/NCT01030861 (Date last accessed: 2 August 2023)."},{"key":"ref101","unstructured":"Clinicaltrials.gov. At-risk for type 1 diabetes extension study. ClinicalTrials.gov identifier: NCT04270942. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04270942 (Date last accessed: 10 July 2023)."},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Lundgren M, Jonsdottir B, Elding Larsson H, DiPiS study group. Effect of screening for type 1 diabetes on early metabolic control: The DiPiS study.\n                      Diabetologia\n                      . 2019;62:53\u20137. DOI: 10.1007\/s00125-018-4706-z.","DOI":"10.1007\/s00125-018-4706-z"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Besser REJ, Ng SM, Robertson EJ. Screening children for type 1 diabetes.\n                      BMJ\n                      . 2021;375:e067937. DOI: 10.1136\/bmj-2021-067937.","DOI":"10.1136\/bmj-2021-067937"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Mullard A. FDA approves anti-CD3 antibody to delay type 1 diabetes onset.\n                      Nat Rev Drug Discov\n                      . 2023;22:6\u20137. DOI: 10.1038\/d41573-022-00198-9.","DOI":"10.1038\/d41573-022-00198-9"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Perdigoto AL, Preston-Hurlburt P, Clark P, et al. Treatment of type 1 diabetes with teplizumab: Clinical and immunological follow-up after 7 years from diagnosis.\n                      Diabetologia\n                      . 2019;62:655\u201364. DOI: 10.1007\/s00125-018-4786-9.","DOI":"10.1007\/s00125-018-4786-9"},{"key":"ref106","unstructured":"Clinicaltrials.gov. Type 1 Diabetes Extension Study (T1DES). ClinicalTrials.gov identifier: NCT02734277. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02734277 (Date last accessed: 10 July 2023)."},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Streisand R, Monaghan M. Young children with type 1 diabetes: Challenges, research, and future directions.\n                      Curr Diab Rep\n                      . 2014;14:520. DOI: 10.1007\/s11892-014-0520-2.","DOI":"10.1007\/s11892-014-0520-2"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Ovalle F, Grimes T, Xu G, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes.\n                      Nat Med\n                      . 2018;24:1108\u201312. DOI: 10.1038\/s41591-018-0089-4.","DOI":"10.1038\/s41591-018-0089-4"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Dutta D, Nagendra L, Raizada N, et al. Verapamil improves one-year C-peptide levels in recent onset type-1 diabetes: A meta-analysis.\n                      Indian J Endocrinol Metab\n                      . 2023;27:192\u2013200. DOI: 10.4103\/ijem.ijem_122_23.","DOI":"10.4103\/ijem.ijem_122_23"}],"container-title":["touchREVIEWS in Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/diabetes\/journal-articles\/teplizumab-in-type-1-diabetes-mellitus-an-updated-review\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:24Z","timestamp":1764745164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/diabetes\/journal-articles\/teplizumab-in-type-1-diabetes-mellitus-an-updated-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"alternative-id":["EE.2023.19.2.7"],"URL":"https:\/\/doi.org\/10.17925\/ee.2023.19.2.7","relation":{},"ISSN":["1758-3772"],"issn-type":[{"value":"1758-3772","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}